Quarterly report pursuant to Section 13 or 15(d)

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details)

v3.22.2.2
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Earnings Per Share [Abstract]        
Net loss before noncontrolling interests $ (29,101) $ (12,670) $ (48,734) $ (22,779)
Net loss attributable to noncontrolling interest 3,576 1,199 6,337 1,877
Net loss - as reported, attributable to PAVmed Inc. (25,525) (11,471) (42,397) (20,902)
Series B Convertible Preferred Stock dividends – earned (70) (74) (138) (149)
Net loss attributable to PAVmed Inc. common stockholders $ (25,595) $ (11,545) $ (42,535) $ (21,051)
Weighted average common shares outstanding, basic and diluted 86,957,352 82,235,397 86,689,857 78,117,637
Net loss - as reported, attributable to PAVmed Inc. $ (0.29) $ (0.14) $ (0.49) $ (0.27)
Net loss attributable to PAVmed Inc. common stockholders $ (0.29) $ (0.14) $ (0.49) $ (0.27)